X Zhang1, X Miao, T Sun, W Tan, S Qu, P Xiong, Y Zhou, D Lin. 1. Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
BACKGROUND: The FAS and FASL system plays a key role in regulating apoptotic cell death and corruption of this signalling pathway has been shown to participate in immune escape and tumorigenesis. There is reduced expression of FAS but elevated expression of FASL in many types of human cancers including lung cancer. We recently reported an association between functional polymorphisms in FAS (-1377G-->A) and FASL (-844T-->C) and risk of oesophageal cancer. OBJECTIVE: To examine the contribution of these polymorphisms to risk of developing lung cancer. METHODS: Genotypes of 1000 lung cancer patients and 1270 controls were analysed by PCR based restriction fragment length polymorphism. Associations with risk of lung cancer were estimated by logistic regression. RESULTS: Compared with non-carriers, there was a 1.6 fold excess risk of developing lung cancer for carriers of the FAS -1377AA genotype (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.21 to 2.10; p = 0.001), and 1.8 fold excess risk (OR 1.79, 95% CI 1.26 to 2.52; p = 0.001) for carriers of FASL -844CC. Gene-gene interaction of FAS and FASL polymorphisms increased risk of lung cancer in a multiplicative manner (OR for the carriers of both FAS -1377AA and FASL -844CC genotypes 4.18, 95% CI 2.83 to 6.18). Gene-environment interaction of FAS or FASL polymorphism and smoking associated with increased risk of lung cancer was also found. CONCLUSION: These results are consistent with our initial findings in oesophageal cancer and further support the hypothesis that the FAS and FASL triggered apoptosis pathway plays an important role in human carcinogenesis.
BACKGROUND: The FAS and FASL system plays a key role in regulating apoptotic cell death and corruption of this signalling pathway has been shown to participate in immune escape and tumorigenesis. There is reduced expression of FAS but elevated expression of FASL in many types of humancancers including lung cancer. We recently reported an association between functional polymorphisms in FAS (-1377G-->A) and FASL (-844T-->C) and risk of oesophageal cancer. OBJECTIVE: To examine the contribution of these polymorphisms to risk of developing lung cancer. METHODS: Genotypes of 1000 lung cancerpatients and 1270 controls were analysed by PCR based restriction fragment length polymorphism. Associations with risk of lung cancer were estimated by logistic regression. RESULTS: Compared with non-carriers, there was a 1.6 fold excess risk of developing lung cancer for carriers of the FAS -1377AA genotype (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.21 to 2.10; p = 0.001), and 1.8 fold excess risk (OR 1.79, 95% CI 1.26 to 2.52; p = 0.001) for carriers of FASL -844CC. Gene-gene interaction of FAS and FASL polymorphisms increased risk of lung cancer in a multiplicative manner (OR for the carriers of both FAS -1377AA and FASL -844CC genotypes 4.18, 95% CI 2.83 to 6.18). Gene-environment interaction of FAS or FASL polymorphism and smoking associated with increased risk of lung cancer was also found. CONCLUSION: These results are consistent with our initial findings in oesophageal cancer and further support the hypothesis that the FAS and FASL triggered apoptosis pathway plays an important role in humancarcinogenesis.
Authors: S H Lee; M S Shin; W S Park; S Y Kim; S M Dong; J H Pi; H K Lee; H S Kim; J J Jang; C S Kim; S H Kim; J Y Lee; N J Yoo Journal: Cancer Res Date: 1999-07-01 Impact factor: 12.701
Authors: B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: Wolfram V Bernstorff; Jonathan N Glickman; Robert D Odze; Francis A Farraye; Hong G Joo; Peter S Goedegebuure; Timothy J Eberlein Journal: Cancer Date: 2002-05-15 Impact factor: 6.860
Authors: Jianming Wu; Christine Metz; Xiulong Xu; Riichiro Abe; Andrew W Gibson; Jeffrey C Edberg; Jennifer Cooke; Fenglong Xie; Glinda S Cooper; Robert P Kimberly Journal: J Immunol Date: 2003-01-01 Impact factor: 5.422
Authors: Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Therese Truong; Wiebke Sauter; James D McKay; H Dean Hosgood; Carla Gallagher; Christopher I Amos; Margaret Spitz; Joshua Muscat; Philip Lazarus; Thomas Illig; H Erich Wichmann; Heike Bickeböller; Angela Risch; Hendrik Dienemann; Zuo-Feng Zhang; Behnaz Pezeshki Naeim; Ping Yang; Shanbeh Zienolddiny; Aage Haugen; Loïc Le Marchand; Yun-Chul Hong; Jin Hee Kim; Eric J Duell; Angeline S Andrew; Chikako Kiyohara; Hongbing Shen; Keitaro Matsuo; Takeshi Suzuki; Adeline Seow; Daniel P K Ng; Qing Lan; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Vali Constantinescu; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Neil E Caporaso; Demetrius Albanes; Michael Thun; Maria Teresa Landi; Joanna Trubicka; Marcin Lener; Jan Lubinski; Ying Wang; Amélie Chabrier; Paolo Boffetta; Paul Brennan; Rayjean J Hung Journal: Carcinogenesis Date: 2010-01-27 Impact factor: 4.944
Authors: Fenghua Zhang; Erich M Sturgis; Yan Sun; Yang Zhang; Qingyi Wei; Caiyun Zhang; Hongliang Zheng; Guojun Li Journal: Int J Cancer Date: 2015-07-27 Impact factor: 7.396
Authors: Rihong Zhai; Feng Chen; Geoffrey Liu; Li Su; Matthew H Kulke; Kofi Asomaning; Xihong Lin; Rebecca S Heist; Norman S Nishioka; Chau-Chyun Sheu; John C Wain; David C Christiani Journal: J Clin Oncol Date: 2010-04-12 Impact factor: 44.544